

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2019

<https://marketpublishers.com/r/C1C9D8A7A0DEN.html>

Date: December 2019

Pages: 615

Price: US\$ 2,000.00 (Single User License)

ID: C1C9D8A7A0DEN

Abstracts

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2019, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline landscape.

Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. Risk factors for CML include high-dose radiation, age and gender. Symptoms include weakness, fatigue, night sweats, weight loss, fever, bone pain, an enlarged spleen and pain or a sense of fullness in the belly. Treatment includes radiation therapy, blood cell transplantation and chemotherapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development

history and latest news and press releases.

The Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 3, 29, 19, 2, 18, 6 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 9, 4, 6 and 3 molecules, respectively.

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology).

The pipeline guide reviews pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products

which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Chronic

Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Overview

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics

Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics

Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Companies Involved
in Therapeutics Development

AbbVie Inc

Agios Pharmaceuticals Inc

Altor Bioscience LLC

Arromax Pharmatech Co Ltd

Ascentage Pharma Group International

AstraZeneca Plc

Atara Biotherapeutics Inc

AUM Biosciences Pte Ltd

Bio-Path Holdings Inc

BioLineRx Ltd

Boston Biomedical Inc

Bristol-Myers Squibb Co

Cantargia AB

Celgene Corp

Celularity Inc

Daiichi Sankyo Co Ltd

Escend Pharmaceuticals Inc

Eureka Therapeutics Inc

ExCellThera Inc

Fate Therapeutics Inc
Fusion Pharma LLC
Gamida Cell Ltd
GlaxoSmithKline Plc
GlycoMimetics Inc
GT Biopharma Inc
Handa Pharmaceuticals LLC
Hebei Senlang Biotechnology Inc Ltd
HEC Pharm Co Ltd
Helocyte Biosciences Inc
HighPass Bio Inc
Housey Pharmaceutical Research Laboratories LLC
Hovione FarmaCiencia SA
Ilyang Pharmaceutical Co Ltd
ImmunoForge Co Ltd
ImmunoGen Inc
Incysus Therapeutics Inc
Incyte Corp
Inhibikase Therapeutics Inc
Johnson & Johnson
Juno Therapeutics Inc
LG Chem Ltd
MAA Laboratories Inc
Magenta Therapeutics Inc
Mana Therapeutics Inc
MedPacto Inc
Millennium Pharmaceuticals Inc
Nanjing Sanhome Pharmaceutical Co Ltd
Natco Pharma Ltd
Nemucore Medical Innovations Inc
Neovia Oncology Inc
Nohla Therapeutics Inc
Novartis AG
OncoTherapy Science Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
Pharma Mar SA
PharmaEssentia Corp
Phylogica Ltd

Prescient Therapeutics Ltd
PRISM Pharma Co Ltd
Shenogen Pharma Group Ltd
Shouyao Holding Co Ltd
SignalChem Lifesciences Corp
Stemline Therapeutics Inc
Sun Pharma Advanced Research Company Ltd
Synactix Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Terns Pharmaceuticals Inc
TheraPharm Deutschland GmbH
Xencor Inc
Xspray Pharma AB
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Drug Profiles
(camptothecin + podofilox) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AIC-47 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALT-803 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMX-5035 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Inhibit MIR126 for Chronic Myelocytic Leukemia - Drug
Profile
Product Description
Mechanism Of Action
R&D Progress
APG-1351 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

asciminib hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATA-520 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AUM-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

azacitidine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

binimetinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BL-8040 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bosutinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Chronic Myeloid Leukemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Hematological Malignancies - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ceralasertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-413 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CYNK-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dasatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dasatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dilanubicel - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ECT-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ES-3000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ET-019002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Chronic Myeloid Leukemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Leukemias - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Target CD19 and CD22 for Acute Lymphocytic Leukemia and Diffuse Large B-Cell Lymphoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Target CD19 for Blood Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Target CD20 for Blood Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Target CD22 for Blood Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Target GM-CSF for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-3326595 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HD-30 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HND-030 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HND-033 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hu8F4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ICS-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

imatinib mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMGN-632 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

inotuzumab ozogamicin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ipilimumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ivosidenib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ixazomib citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JTCR-016 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KF-1601 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lurbinededin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MANA-677679 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGTA-456 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

milademetan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MJ-05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Target CD66b for Blood Cancer and Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

napabucasin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nidanilimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nilotinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nivolumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NMI-900 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NRCAN-019 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omidubicel - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OTS-167 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OXS-3550 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pevonedistat hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress
PF-114 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ponatinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prexigebersen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRI-724 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ProTmune - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
radotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ropeginterferon alfa-2b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ruxolitinib phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-0071235 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCO-088 - Drug Profile
Product Description

Mechanism Of Action

R&D Progress

SENL-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHC-004221A1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLC-391 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Chronic Myelocytic Leukemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit ABL1 for Chronic Myeloid Leukemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit ADAR1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BCR-ABL for ALL and CML - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Bcr-Abl for CML and Pancreatic Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit SIRT1 for Chronic Myelogenous Leukemia - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
SNG-1153 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNG-162 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUNK-0954 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SY-2755 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYN-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit STAT5 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-243 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tipifarnib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TM-5614 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

TR-120 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tricitabine phosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Triplex - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

uproleselan sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Wilms Tumor Protein for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target WT1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vactosertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veliparib ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

venetoclax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XmAb-14045 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Product Development Milestones

Featured News & Press Releases

Dec 10, 2019: Ascentage Pharma releases updated data of its novel BCR-ABL inhibitor, HQP1351, in an oral presentation nominated for "Best of ASH"

Nov 25, 2019: Data from Incyte's Oncology Portfolio including ponatinib hydrochloride accepted for presentation at the 61st Annual ASH Meeting

Nov 14, 2019: Ascentage Pharma to release updated data of its novel, third-generation BCR-ABL inhibitor, HQP1351, in Chinese chronic myeloid leukemia patients in an oral presentation at the 61st American Society of Hematology Annual Meeting

Nov 06, 2019: Takeda to present abstract on ICLUSIG at 61st American Society of Hematology (ASH) Annual Meeting

Jul 21, 2019: Ascentage Pharma to initiate phase Ib study of HQP1351 in tyrosine kinase inhibitors -resistant Chronic Myeloid Leukemia Patients in the US

Jul 08, 2019: SPARC receives Orphan Drug Designation from the USFDA for SCO-088 for the treatment of patients with chronic myeloid leukemia

Jun 14, 2019: Novartis presents on Asciminib at the 24th Congress of the European Hematology Association (EHA) in Amsterdam

Jun 11, 2019: Xspray granted additional product patents in the United States including HyNap-Nilo

May 16, 2019: Bristol-Myers Squibb to present new data on Sprycel at EHA 2019

Feb 19, 2019: Incyte provides statement on World Health Organization Global Medical Product alert for Iclusig (ponatinib)

Jan 18, 2019: EMA recommends extension of existing paediatric indications for Dasatinib

Jan 03, 2019: An errant editing enzyme promotes tumor suppressor loss and leukemia propagation

Dec 27, 2018: Bio-Path Holdings provides clinical update and 2019 business outlook

Dec 03, 2018: Ascentage Pharma announces oral presentation of novel, third-generation BCR-ABL inhibitor in myelogenous leukemia patients at the 60th American Society of Hematology Annual Meeting

Nov 21, 2018: Ascentage Pharma to present new clinical data at the ASH 2018 annual meeting

Appendix

Methodology

[Coverage](#)
[Secondary Research](#)
[Primary Research](#)
[Expert Panel Validation](#)
[Contact Us](#)
[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by AbbVie Inc, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Agios Pharmaceuticals Inc, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Altor Bioscience LLC, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Arramax Pharmatech Co Ltd, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ascentage Pharma Group International, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by AstraZeneca Plc, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Atara Biotherapeutics Inc, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by AUM Biosciences Pte Ltd, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bio-Path Holdings Inc, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BioLineRx Ltd, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Boston Biomedical Inc, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bristol-Myers Squibb Co, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Cantargia

AB, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Celgene Corp, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Celularity Inc, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Daiichi Sankyo Co Ltd, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Escend Pharmaceuticals Inc, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Eureka Therapeutics Inc, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by ExCellThera Inc, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Fate Therapeutics Inc, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Fusion Pharma LLC, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Gamida Cell Ltd, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by GlaxoSmithKline Plc, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by GlycoMimetics Inc, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by GT Biopharma Inc, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Handa Pharmaceuticals LLC, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Hebei Senlang Biotechnology Inc Ltd, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by HEC Pharm Co Ltd, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Helocyte Biosciences Inc, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by HighPass Bio Inc, H2 2019

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Housey Pharmaceutical Research Laboratories LLC, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

COMPANIES MENTIONED

AbbVie Inc

Agios Pharmaceuticals Inc

Altor Bioscience LLC

Arramax Pharmatech Co Ltd

Ascentage Pharma Group International

AstraZeneca Plc

Atara Biotherapeutics Inc

AUM Biosciences Pte Ltd

Bio-Path Holdings Inc

BioLineRx Ltd

Boston Biomedical Inc

Bristol-Myers Squibb Co

Cantargia AB

Celgene Corp

Celularity Inc

Daiichi Sankyo Co Ltd

Escend Pharmaceuticals Inc

Eureka Therapeutics Inc

ExCellThera Inc

Fate Therapeutics Inc

Fusion Pharma LLC
Gamida Cell Ltd
GlaxoSmithKline Plc
GlycoMimetics Inc
GT Biopharma Inc
Handa Pharmaceuticals LLC
Hebei Senlang Biotechnology Inc Ltd
HEC Pharm Co Ltd
Helocyte Biosciences Inc
HighPass Bio Inc
Housey Pharmaceutical Research Laboratories LLC
Hovione FarmaCiencia SA
Ilyang Pharmaceutical Co Ltd
ImmunoForge Co Ltd
ImmunoGen Inc
Incysus Therapeutics Inc
Incyte Corp
Inhibikase Therapeutics Inc
Johnson & Johnson
Juno Therapeutics Inc
LG Chem Ltd
MAA Laboratories Inc
Magenta Therapeutics Inc
Mana Therapeutics Inc
MedPacto Inc
Millennium Pharmaceuticals Inc
Nanjing Sanhome Pharmaceutical Co Ltd
Natco Pharma Ltd
Nemucore Medical Innovations Inc
Neovia Oncology Inc
Nohla Therapeutics Inc
Novartis AG
OncoTherapy Science Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
Pharma Mar SA
PharmaEssentia Corp
Phylogica Ltd
Prescient Therapeutics Ltd

PRISM Pharma Co Ltd
Shenogen Pharma Group Ltd
Shouyao Holding Co Ltd
SignalChem Lifesciences Corp
Stemline Therapeutics Inc
Sun Pharma Advanced Research Company Ltd
Synactix Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Terns Pharmaceuticals Inc
TheraPharm Deutschland GmbH

I would like to order

Product name: Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/C1C9D8A7A0DEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C1C9D8A7A0DEN.html>